Yinyan Wang | Neuroimaging Award | Best Researcher Award

Posted on by ScienceFather

Dr. Yinyan Wang | Neuroimaging Award | Best Researcher Award

Dr. Yinyan Wang, Bejing Tiantan Hospital, China

Dr. Yinyan Wang, an accomplished neurosurgeon and researcher, serves as an Attending Surgeon at Beijing Tiantan Hospital. With expertise in brain functional mapping and radiomics, he has authored 70 SCI publications and holds several national patents. Dr. Wang leads prominent projects including the Beijing Natural Science Foundation and National Natural Science Foundation initiatives. His contributions to neurosurgery include pioneering methods in functional MRI and glioma research, recognized with multiple prestigious awards. As PI of China National Clinical Research Center for Neurological Diseases and China Institute for Brain Research, he continues to advance neuroscience, integrating international training from Finland, Germany, and the Netherlands. 🧠✨

 

Publication profile

🎓 Education Background

He obtained his Ph.D. and Master’s degrees in Neurosurgery from Capital Medical University, following a Bachelor’s in Clinical Medicine.

👨‍⚕️ Working Experience

Starting as a resident doctor and now serving as Deputy Chief Surgeon, his career highlights include roles as Associate Professor and Attending Surgeon.

🏆 Awards

Recognized for his contributions, he holds key positions in national research centers and medical committees, driving advancements in neurology.

 

 

Research Focus

Dr. Wang Y. focuses on advancing the understanding and treatment of neurological conditions, particularly gliomas. His research spans diverse areas including pre-operative brain mapping and radiomics-based machine learning for brain tumors. 🧠 His contributions are widely recognized with numerous publications in esteemed journals, showcasing innovative approaches in clinical neuroimaging and neurosurgery. Dr. Wang’s work not only enhances surgical techniques but also pioneers new methods in functional MRI and data analysis. His commitment to improving outcomes for patients with brain tumors underscores his significant impact in the field of neuroscience. 🌟

Publication Top Notes

  • Model construction and multi-objective performance optimization of a biodiesel-diesel dual-fuel engine based on CNN-GRU 🚗 Wang, H. et al., Energy, 2024,
  • Structural changes in eloquent cortex secondary to glioma in sensorimotor area 🧠 Guo, Y. et al., Human Brain Mapping, 2024,
  • Construction of digital twin model of engine in-cylinder combustion based on data-driven 🛠️ Hu, D. et al., Energy, 2024,
  • The effect of changing EGR rate on engine performance under different ammonia/methanol ratios 🚚 Yang, C. et al., Journal of the Energy Institute, 2024, Effects of combustion and emission performance of ammonia/natural gas engines ignited by diesel ⛽ Wang, B. et al., Fuel, 2024, cited by: 6
  • Construction and verification of dual-fuel engine combustion model 🔥 Hu, D. et al., Journal of the Energy Institute, 2024,
  • Effect of different ammonia/methanol ratios on engine combustion and emission performance 🌡️ Wang, B. et al., Applied Thermal Engineering, 2024, cited by: 14
  • Research on surrogate models and optimization algorithms of compressor characteristic based on digital twins 🔄 Yang, Q. et al., Journal of Engineering Research (Kuwait), 2024, cited by: 0
  • Effect of different ammonia mixing methods for diesel ignition on combustion and emission performance of high pressure common rail engine 🚛 Wang, B. et al., Journal of the Energy Institute, 2023, cited by: 5
  • Development of an integrated predictive model for postoperative glioma-related epilepsy using gene-signature and clinical data 🧬 Li, L. et al., BMC Cancer, 2023, cited by: 1

Linjing Mu | Brain PET Imaging Award | Best Researcher Award

Posted on by ScienceFather

Dr. Linjing Mu | Brain PET Imaging Award | Best Researcher Award

Dr. Linjing Mu, ETH Zurich, Switzerland

🔬 Dr. Linjing Mu pursued doctoral research at Nankai University, followed by a post-doctoral fellowship at Basel University, Switzerland. With expertise in radiopharmaceutical sciences, Dr. Mu led research teams at University Hospital Zurich and ETH Zurich, focusing on lead structure discovery, ligand synthesis, and radiolabeling method development. A prolific author, Dr. Mu has 106 peer-reviewed publications, including 10 as last and corresponding author, and 19 as the first author. Co-investigator on 10 patents, Dr. Mu has presented internationally and collaborated with industry leaders like Bayer Schering, Novartis, and Roche, contributing significantly to drug discovery and clinical translations.

 

Publication Profile:

Scopus

Orcid

Education:

Doctoral Research in Chemistry Department, Nankai University (1993-1996)

Post-Doctoral Fellow, Basel University, Switzerland (1996-2001)

Experience:

Team Leader in the field of Radiopharmaceutical Sciences, Group of Prof. Schubiger (2001-2010)

Head of Research, Radiopharmacy, University Hospital Zurich (2010-2021)

Senior Scientist, Prof. Schibli’s Group, ETH Zurich (2021-Present)

Research Expertise:

Lead Structure Finding based on Literature and Patents

Design and Synthesis of Novel Ligands

Structure-Activity Relationship Studies

Radiolabeling Method Development

In Vitro and In Vivo Evaluation

Academic Achievements:

Co-authored 106 Peer-Reviewed Publications

Last and Corresponding Author on 10, First Author on 19 (H-Factor 29, Scopus)

Co-Investigator on 10 Patent Applications

Contributed to International Conferences as Invited Speaker, Oral and Poster Presenter

Research Focus:

🔬 Dr. Linjing Mu’s research focus lies at the intersection of neuroimaging and drug development, particularly in the field of molecular imaging for neurodegenerative diseases like Alzheimer’s. Their work encompasses the development and optimization of radioligands targeting specific molecular pathways implicated in neurodegeneration. Through PET/MRI studies and the exploration of novel PET tracers, such as (R)-[18F]YH134 and (R)-[18F]PSS232, Dr. Mu aims to deepen our understanding of disease mechanisms and identify potential therapeutic targets. This research not only sheds light on disease pathology but also paves the way for the development of new diagnostic tools and pharmacological interventions.

 

Publication Top Notes:

📄 Wang, J. et al. Metabotropic glutamate receptor 5 (mGluR5) is associated with neurodegeneration and amyloid deposition in Alzheimer’s disease: A [18F]PSS232 PET/MRI study. Published in Alzheimer’s Research and Therapy, 2024. Cited by: 0.

📄 He, Y. et al. Identification of (R)-[18F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development. Published in Journal of Nuclear Medicine, 2024. Cited by: 0.

📄 Boccalini, C. et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Published in Alzheimer’s and Dementia, 2024. Cited by: 1.

📄 Trachsel, B. et al. Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK. Published in EJNMMI Radiopharmacy and Chemistry, 2023. Cited by: 0.

📄 Lu, Y. et al. Proof-of-concept optimization of a copper-mediated 18F-radiosynthesis of a novel MAGL PET tracer on a high-throughput microdroplet platform and its macroscale translation. Published in Lab on a Chip, 2023. Cited by: 1.

📄 Ni, R. et al. Imaging increased metabolism in the spinal cord in mice after middle cerebral artery occlusion. Published in Photoacoustics, 2023. Cited by: 0.

📄 Zechner, M. et al. In Vitro and In Vivo Evaluation of ABCG2 (BCRP) Inhibitors Derived from Ko143. Published in Journal of Medicinal Chemistry, 2023. Cited by: 1.

📄 Bengs, S. et al. Rest/stress myocardial perfusion imaging by positron emission tomography with 18F-Flurpiridaz: A feasibility study in mice. Published in Journal of Nuclear Cardiology, 2023. Cited by: 3.

📄 Peretti, D.E. et al. ATN profile classification across two independent prospective cohorts. Published in Frontiers in Medicine, 2023. Cited by: 0.

📄 He, Y. et al. Multi-parameter optimization: Development of a morpholin-3-one derivative with an improved kinetic profile for imaging monoacylglycerol lipase in the brain. Published in European Journal of Medicinal Chemistry, 2022. Cited by: 2.